BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies
BenevolentAI (Euronext Amsterdam: BAI), a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces the successful delivery of its pre-clinical candidate for the potential treatment of...